Department of Biochemistry, University of Oxford, Oxford OX1 3QU, U.K.
Biochem Soc Trans. 2020 Apr 29;48(2):337-346. doi: 10.1042/BST20180302.
Solute carrier (SLC) transporters play important roles in regulating the movement of small molecules and ions across cellular membranes. In mammals, they play an important role in regulating the uptake of nutrients and vitamins from the diet, and in controlling the distribution of their metabolic intermediates within the cell. Several SLC families also play an important role in drug transport and strategies are being developed to hijack SLC transporters to control and regulate drug transport within the body. Through the addition of amino acid and peptide moieties several novel antiviral and anticancer agents have been developed that hijack the proton-coupled oligopeptide transporters, PepT1 (SCL15A1) and PepT2 (SLC15A2), for improved intestinal absorption and renal retention in the body. A major goal is to understand the rationale behind these successes and expand the library of prodrug molecules that utilise SLC transporters. Recent co-crystal structures of prokaryotic homologues of the human PepT1 and PepT2 transporters have shed important new insights into the mechanism of prodrug recognition. Here, I will review recent developments in our understanding of ligand recognition and binding promiscuity within the SLC15 family, and discuss current models for prodrug recognition.
溶质载体(SLC)转运蛋白在调节小分子和离子跨细胞膜的运动方面发挥着重要作用。在哺乳动物中,它们在调节从饮食中摄取营养物质和维生素,以及控制其代谢中间产物在细胞内的分布方面发挥着重要作用。几个 SLC 家族在药物转运中也起着重要作用,目前正在开发劫持 SLC 转运蛋白的策略来控制和调节体内的药物转运。通过添加氨基酸和肽片段,已经开发出几种新型的抗病毒和抗癌药物,它们劫持质子偶联寡肽转运蛋白 PepT1(SCL15A1)和 PepT2(SLC15A2),以改善肠道吸收和体内的肾脏保留。一个主要目标是了解这些成功背后的原理,并扩大利用 SLC 转运蛋白的前药分子库。最近,人类 PepT1 和 PepT2 转运蛋白原核同源物的共晶结构为前药识别的机制提供了重要的新见解。在这里,我将回顾我们对 SLC15 家族中配体识别和结合的多样性的最新理解,并讨论当前的前药识别模型。